Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEB-BACE with Anlotinib and Adebrelimab in Advanced NSCLC
NCT06188650Recruiting
- Sponsor
- Ningbo Medical Centre Lihuili Hospital
- Start
- Dec 2023
- Primary completion
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Open-label, single-arm trial of adebrelimab in non-small cell lung cancer (NSCLC), sponsored by Ningbo Medical Centre Lihuili Hospital. Primary endpoint: Objective Response Rate at 1 year. Started Dec 2023; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06188650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06188650.